Foamy Virus Vectors for HIV Gene Therapy
AbstractHighly active antiretroviral therapy (HAART) has vastly improved outcomes for patients infected with HIV, yet it is a lifelong regimen that is expensive and has significant side effects. Retroviral gene therapy is a promising alternative treatment for HIV/AIDS; however, inefficient gene delivery to hematopoietic stem cells (HSCs) has so far limited the efficacy of this approach. Foamy virus (FV) vectors are derived from non-pathogenic viruses that are not endemic to the human population. FV vectors have been used to deliver HIV-inhibiting transgenes to human HSCs, and they have several advantages relative to other retroviral vectors. These include an attractive safety profile, broad tropism, a large transgene capacity, and the ability to persist in quiescent cells. In addition, the titers of FV vectors are not reduced by anti-HIV transgenes that affect the production of lentivirus (LV) vectors. Thus FV vectors are very promising for anti-HIV gene therapy. This review covers the advantages of FV vectors and describes their preclinical development for anti-HIV gene therapy. View Full-Text
Share & Cite This Article
Olszko, M.E.; Trobridge, G.D. Foamy Virus Vectors for HIV Gene Therapy. Viruses 2013, 5, 2585-2600.
Olszko ME, Trobridge GD. Foamy Virus Vectors for HIV Gene Therapy. Viruses. 2013; 5(10):2585-2600.Chicago/Turabian Style
Olszko, Miles E.; Trobridge, Grant D. 2013. "Foamy Virus Vectors for HIV Gene Therapy." Viruses 5, no. 10: 2585-2600.